{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"semaglutide-statins","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-statins/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/semaglutide-statins/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-statins/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-statins/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-statins/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-statins/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/semaglutide-statins/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"semaglutide-statins","title":"semaglutide statins","register":"standard","tags":[],"updated_at":"2026-07-17T02:41:49.415Z","body_excerpt":"## Overview\nEvidence is being populated by Grok web search.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c4","text":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c7","text":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s7"],"source_status":"sourced","why_material":"Materialized from orphan source s7 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c8","text":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s8"],"source_status":"sourced","why_material":"Materialized from orphan source s8 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c9","text":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s9"],"source_status":"sourced","why_material":"Materialized from orphan source s9 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c_map_semaglutide-statins","text":"Combinatorial mapping (transparent): semaglutide vs statins — regen=0.32, degen=0.45, Δ=-0.13. Method: layer_relevance(0.60) × evidence_factor(0.40); catalog.degen_score for Statins.","tier":"runtime","weight":0.35,"section":"what_is_known","interaction_risk":false,"status":"active","source_ids":[],"retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.35,"quote_gated":false},{"id":"c3","text":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","tier":"mechanistic","weight":0.3,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c5","text":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c6","text":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s6"],"source_status":"sourced","why_material":"Materialized from orphan source s6 by ledger repair","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","summary":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb"},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","summary":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","summary":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","claim_ids":["c6"],"link_status":"ok","quote_status":"unverified","hash":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4"},{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","claim_ids":["c7"],"link_status":"ok","quote_status":"verified","hash":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f"},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","summary":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","claim_ids":["c8"],"link_status":"ok","quote_status":"verified","hash":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","summary":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","claim_ids":["c9"],"link_status":"ok","quote_status":"verified","hash":"47911d0481591ba31783e80cc560ef599eaac7c3360fd26887039bd11d8a73b1"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","summary":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb"},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","summary":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","summary":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","claim_ids":["c6"],"link_status":"ok","quote_status":"unverified","hash":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4"},{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","claim_ids":["c7"],"link_status":"ok","quote_status":"verified","hash":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f"},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","summary":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","claim_ids":["c8"],"link_status":"ok","quote_status":"verified","hash":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","summary":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","claim_ids":["c9"],"link_status":"ok","quote_status":"verified","hash":"47911d0481591ba31783e80cc560ef599eaac7c3360fd26887039bd11d8a73b1"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"semaglutide-statins","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":10,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":10,"claims_total":10,"sources":9,"anecdotal":0,"scientific":9,"user_reports":0,"questions":0,"evidence_ingests":0}}